Cycuity Inc.
Total Consideration
$45.0M
Arteris, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$-0
Free Cash Flow Per Share
$0
Cash Per Share
$1
Revenue Per Share
$2
OCF Per Share
$0
Return on Equity
439.3%
Return on Assets
-31.4%
Return on Invested Capital
331.0%
Current Ratio
1.13
Quick Ratio
1.13
Asset Turnover
0.64
Days Sales Outstanding
99.21
Days Payables Outstanding
18.00
R&D / Revenue
70.7%
SBC / Revenue
26.0%
Capex / Revenue
2.0%
Working Capital
$9M
Net Current Asset Value
$-47M
Invested Capital
$-15M
OCF / Net Income
-0.19
FCF / Net Income
-0.15
Accruals Ratio (Sloan)
-36.1%
Net Debt
$-34M
Net Debt / EBITDA
1.14
Interest Coverage
-171.69
Cash Coverage
34.89
Capex Coverage
4.85
Tangible Common Equity
$-21M
TCE / Total Assets
-18.2%
Goodwill / Total Assets
3.6%
NOPAT
$-26M
Cash ROIC
-67.6%
WC / Revenue
13.0%
Capex / D&A
0.41
Reinvestment Rate
6.0%
Asset Growth vs Revenue Growth
-13.9%
Revenue 5Y CAGR
17.3%
FCF 5Y CAGR
28.8%
Stock Price (FY-end)
$16
Market Cap
$656M
P/S Ratio
9.29
P/B Ratio
—
P/TB Ratio
—
P/OCF Ratio
97.36
P/FCF Ratio
122.64
Enterprise Value
$622M
EV / Sales
8.81
EV / FCF
116.30
FCF Yield
0.8%
Shareholder Yield
-2.8%
R&D Yield
7.6%
Capex Yield
0.2%
Shares Variation (YoY)
8.7%
Beta (5Y)
1.89
Cost of Equity
14.0%
52W High
$20
52W Low
$6
Trailing Return 1Y
50.9%
F-Score (Piotroski)
5.00
Z-Score (Altman)
0.70
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
Arteris, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 10.00% | 0.60% | 3.90% | 1.30% | 1.60% | 0.40% |
| Foreign Rate Differential | 6.80% | 6.00% | 0.10% | -3.40% | -2.70% | — |
| Other Adjustments | 0.40% | 0.80% | 3.10% | -1.40% | -0.20% | -0.10% |
| R&D Tax Credits | — | — | — | — | — | -3.20% |
| FDII Deduction | — | — | — | — | — | -1.30% |
| SBC (Nondeductible) | 1.20% | -1.00% | -0.90% | -3.60% | -2.30% | — |
| Nondeductible Expenses | — | — | — | — | — | -1.40% |
| Valuation Allowance Change | -86.70% | -33.10% | -28.30% | -20.90% | -26.30% | -11.10% |
| Tax Law Change | — | — | — | — | — | 0.00% |
| Effective Tax Rate | -45.90% | -4.70% | 1.50% | -4.80% | -8.00% | -4.40% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $1.0M | $1.0M | −$417.0K | $1.7M | $2.5M | $1.5M |
| Income Taxes Paid (Cash) | $1.5M | $489.0K | $790.0K | $1.3M | $1.6M | $2.8M |
Arteris, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.